Melatonin and synthetic melatonergic agonists: Actions and metabolism in the central nervous system

Central Nervous System Agents in Medicinal Chemistry

Volumn 12, Issue 3, 2012, Pages 189-216

  Hardeland, R ^a,b   Poeggeler, B ^a,b,c  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b Center for Systems Neuroscience   (Germany)

^c QUIRIS HEALTHCARE ^*  (Germany)

Author keywords

Agomelatine; Depression; Kynuramines; Melatonin; N acetylserotonin; Ramelteon; Sleep; Tasimelteon; TIK 301

Indexed keywords

5 METHOXYTRYPTAMINE; 5 METHOXYTRYPTOPHOL; 6 HYDROXYMELATONIN O SULFATE; ACETYLSEROTONIN METHYLTRANSFERASE; AGOMELATINE; ALDEHYDE DEHYDROGENASE; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; BETA METHYL 6 CHLOROMELATONIN; CYTOCHROME P450 1A1; CYTOCHROME P450 1A2; CYTOCHROME P450 2C; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A; HORMONE RECEPTOR STIMULATING AGENT; KYNURAMINE; MA 1; MELATONIN; MELATONIN 1 RECEPTOR; MELATONIN 2 RECEPTOR; N ACETYLSEROTONIN; PEROXIDASE; RAMELTEON; REACTIVE OXYGEN METABOLITE; RECEPTOR SUBTYPE; SEROTONIN 2C ANTAGONIST; SIRTUIN 1; TASIMELTEON; TIK 301; UCM 765; UCM 924; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; CENTRAL NERVOUS SYSTEM; CHRONOBIOLOGY; CIRCADIAN RHYTHM; CIRCULATION; CONTROLLED RELEASE FORMULATION; DARKNESS; DRUG METABOLISM; FEEDBACK SYSTEM; GABAERGIC SYSTEM; HORMONE METABOLISM; HORMONE SYNTHESIS; HUMAN; INSOMNIA; MAJOR DEPRESSION; MAMMAL; NONHUMAN; PINEAL BODY; RECEPTOR AFFINITY; SIGNAL TRANSDUCTION; SLEEP DISORDER; SUPRACHIASMATIC NUCLEUS; TRANQUILIZING ACTIVITY;

ACETAMIDES; ANIMALS; ANTIDEPRESSIVE AGENTS; CENTRAL NERVOUS SYSTEM; HUMANS; INDENES; MELATONIN; RECEPTORS, MELATONIN; SLEEP;

EID: 84866653643     PISSN: 18715249     EISSN: 18756166     Source Type: Journal    
DOI: 10.2174/187152412802430129     Document Type: Article

References (389)

1. Lerner, A.B.; Case, J.D.; Takahashi, Y. Isolation of melatonin, a pineal factor that lightens melanocytes. J. Am. Chem. Soc., 1958, 80, 2057-2058.
2. Hardeland, R.; Cardinali, D.P.; Srinivasan, V.; Spence, D.W.; Brown, G.M.; Pandi-Perumal, S.R. Melatonin-A pleiotropic, orchestrating regulator molecule. Prog. Neurobiol., 2011, 93, 350-384.
3. Hardeland, R.; Madrid, J.A.; Tan, D.-X.; Reiter, R.J. Melatonin, the circadian multioscillator system and health: the need for detailed analyses of peripheral melatonin signaling. J. Pineal Res., 2011, 52, 139-166.
4. Hardeland, R.; Poeggeler, B. Melatonin beyond its classical functions. Open Physiol. J., 2008, 1, 1-23.
5. Hardeland, R. Melatonin, hormone of darkness and more-occurrence, control mechanisms, actions and bioactive metabolites. Cell. Mol. Life Sci., 2008, 65, 2001-2018.
6. Huether, G. The contribution of extrapineal sites of melatonin synthesis to circulating melatonin levels in higher vertebrates. Experientia, 1993, 49, 665-670.
7. Bubenik, G.A. Gastrointestinal melatonin: localization, function, and clinical relevance. Dig. Dis. Sci., 2002, 47, 2336-2348.
8. Tan, D.-X.; Manchester, L.C.; Hardeland, R.; Lopez-Burillo, S.; Mayo, J.C.; Sainz, R.M.; Reiter, R.J. Melatonin: a hormone, a tissue factor, an autocoid, a paracoid, and an antioxidant vitamin. J. Pineal Res., 2003, 34, 75-78.
9. Pandi-Perumal, S.R.; Srinivasan, V.; Maestroni, G.J.M.; Cardinali, D.P.; Poeggeler, B.; Hardeland, R. Melatonin-Nature's most versatile biological signal? FEBS J., 2006, 273, 2813-2838.
10. Hardeland, R. Melatonin: Signaling mechanisms of a pleiotropic agent. BioFactors, 2009, 35, 183-192.
11. Reiter, R. J,: Tan, D.-X.; Fuentes-Broto, L. Melatonin: a multitasking molecule. Prog. Brain Res., 2010, 181, 127-151.
12. Reiter, R.J. The melatonin rhythm: both a clock and a calendar. Experientia, 1993, 49, 654-664.
13. Perreau-Lenz, S.; Kalsbeek, A.; Garidou, M.L.; Wortel, J.; van der Vliet, J.; van Heijningen, C.; Simonneaux, V.; Pévet, P.; Buijs, R.M. Suprachiasmatic control of melatonin synthesis in rats: inhibitory and stimulatory mechanisms. Eur. J. Neurosci., 2003, 17, 221-228.
14. Hardeland, R. Melatonin in aging and disease μ multiple consequences of reduced secretion, options and limits of treatment. Aging Dis., 2012, 3, 194-225.
15. DeMuro, R.L.; Nafziger, A.N.; Blask, D.E.; Menhinick, A.M.; Bertino, J.S. Jr. The absolute bioavailability of oral melatonin. J. Clin. Pharmacol., 2000, 40, 781-784.
16. Claustrat, B.; Brun, J.; Chazot, G. The basic physiology and pathophysiology of melatonin. Sleep Med. Rev., 2005, 9, 11-24.
17. Hardeland, R. New approaches in the management of insomnia: weighing the advantages of prolonged release melatonin and synthetic melatoninergic agonists. Neuropsychiatr. Dis. Treat., 2009, 5, 341-354.
18. Poeggeler, B.; Cornélissen, G.; Huether, G.; Hardeland, R.; Józsa, R.; Zeman, M.; Stebelova, K.; Oláh, A.; Bubenik, G.; Pan, W.; Otsuka, K.; Schwartzkopff, O.; Bakken, E.E.; Halberg, F. Chronomics affirm extending scope of lead in phase of duodenal vs. pineal circadian melatonin rhythms. Biomed. Pharmacother., 2005, 59, S220-S224.
19. Klein DC. Arylalkylamine N-acetyltransferase: "the timezyme". J. Biol. Chem., 2007, 282, 4233-4237.
20. Ribelayga, C.; Pévet, P.; Simonneaux, V. HIOMT drives the photoperiodic changes in the amplitude of the melatonin peak of the Siberian hamster. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2000, 278, R1339-R1345.
21. Liu, T.; Borjigin, J. N-acetyltransferase is not the rate-limiting enzyme of melatonin synthesis at night. J. Pineal Res., 2005, 39, 91-96.
22. Gamse, J.T.; Shen, Y.C.; Thisse, C.; Thisse, B.; Raymond, P.A.; Halpern, M.E.; Liang, J.O. Otx5 regulates genes that show circadian expression in the zebrafish pineal complex. Nat. Genet., 2002, 30, 117-121.
23. Appelbaum, L.; Vallone, D.; Anzulovich, A.; Ziv, L.; Tom, M.; Foulkes, N.S.; Gothilf, Y. Zebrafish arylalkylamine-Nacetyltransferase genes-targets for regulation of the circadian clock. J. Mol. Endocrinol., 2006, 36, 337-347.
24. Muñoz, E.; Brewer, M.; Baler, R. Modulation of BMAL/CLOCK/E-Box complex activity by a CT-rich cis-acting element. Mol. Cell. Endocrinol., 2006, 252, 74-81.
25. Roseboom, P.H.; Coon, S.L.; Baler, R.; McCune, S.K.; Weller, J.L.; Klein, D.C. Melatonin synthesis: analysis of the more than 150-fold nocturnal increase in serotonin N-acetyltransferase messenger ribonucleic acid in the rat pineal gland. Endocrinology, 1996, 137, 3033-3045.
26. Koch, M.; Mauhin, V.; Stehle, J.H.; Schomerus, C.; Korf, H.W. Dephosphorylation of pCREB by protein serine/threonine phosphatases is involved in inactivation of Aanat gene transcription in rat pineal gland. J. Neurochem., 2003, 85, 170-179.
27. Karolczak, M.; Korf, H.W.; Stehle, J.H. The rhythm and blues of gene expression in the rodent pineal gland. Endocrine, 2005, 27, 89-100.
28. Ganguly, S.; Gastel, J.A.; Weller, J.L.; Schwartz, C.; Jaffe, H.; Namboodiri, M.A.; Coon, S.L.; Hickman, A.B.; Rollag, M.; Obsil, T.; Beauverger, P.; Ferry, G.; Boutin, J.A.; Klein, D.C. Role of a pineal cAMP-operated arylalkylamine N-acetyltransferase/14-3-3-binding switch in melatonin synthesis. Proc. Natl. Acad. Sci. USA, 2001, 98, 8083-8088.
29. Choi, B.H.; Chae, H.D.; Park, T.J.; Oh, J.; Lim, J.; Kang, S.S.; Ha, H.; Kim, K.T. Protein kinase C regulates the activity and stability of serotonin N-acetyltransferase. J. Neurochem., 2004, 90, 442-454.
30. Schomerus, C.; Korf, H.W.; Laedtke, E.; Weller, J.L.; Klein, D.C. Selective adrenergic/cyclic AMP-dependent switch-off of proteasomal proteolysis alone switches on neural signal transduction: an example from the pineal gland. J. Neurochem., 2000, 75, 2123-2132.
31. Tosini, G.; Menaker, M. Circadian rhythms in cultured mammalian retina. Science, 1996, 272, 419-421.
32. Tosini, G., Chaurasia S.S.; Iuvone, P.M. Regulation of arylalkylamine N-acetyltransferase (AANAT) in the retina. Chronobiol. Int., 2006, 23, 381-391.
33. Lundmark, P.O.; Pandi-Perumal, S.R.; Srinivasan, V.; Cardinali, D.P. Role of melatonin in the eye and ocular dysfunctions. Vis. Neurosci., 2006, 23, 853-862.
34. Bernard, M.; Donohue, S.J.; Klein, D.C. Human hydroxyindole-Omethyltransferase in pineal gland, retina and Y79 retinoblastoma cells. Brain Res., 1995, 696, 37-48.
35. Zmijewski, M.A.; Sweatman, T.W.; Slominski, A.T. The melatoninproducing system is fully functional in retinal pigment epithelium (ARPE-19). Mol. Cell. Endocrinol., 2009, 307, 211-216.
36. Fukuda, T.; Akiyama, N.; Ikegami, M.; Takahashi, H.; Sasaki, A.; Oka, H.; Komori, T.; Tanaka, Y.; Nakazato, Y.; Akimoto, J.; Tanaka, M.; Okada, Y.; Saito, S. Expression of hydroxyindole-Omethyltransferase enzyme in the human central nervous system and in pineal parenchymal cell tumors. J. Neuropathol. Exp. Neurol., 2010, 69, 498-510.
37. Hardeland, R.; Poeggeler, B. Actions of melatonin, its structural and functional analogs in the central nervous system and the significance of metabolism. Central Nerv. Syst. Agents Med. Chem., 2007, 7, 289-303.
38. Hardeland, R. Melatonin metabolism in the central nervous system. Curr. Neuropharmacol., 2010, 8, 168-181.
39. Takeuchi, A.;Takeuchi, M.; Oikawa, K.; Sonoda, K.H.; Usui, Y.; Okunuki, Y.; Takeda, A.; Oshima, Y.; Yoshida, K.; Usui, M.; Goto, H.; Kuroda, M. Effects of dioxin on vascular endothelial growth factor (VEGF) production in the retina associated with choroidal neovascularization. Invest. Ophthalmol. Vis. Sci., 2009, 50, 3410-3416.
40. Milstien, S.; Kaufman, S. Tetrahydro-sepiapterin is an intermediate in tetrahydrobiopterin biosynthesis. Biochem. Biophys. Res. Commun., 1983, 115, 888-893.
41. Smith, G.K.; Duch, D.S.; Edelstein, M.P.; Bigham, E.C. New inhibitors of sepiapterin reductase. Lack of an effect of intracellular tetrahydrobiopterin depletion upon in vitro proliferation of two human cell lines. J. Biol. Chem., 1992, 267, 5599-5607.
42. Nagatsu, T.; Ichinose, H. Regulation of pteridine-requiring enzymes by the cofactor tetrahydrobiopterin. Mol. Neurobiol., 1999, 19, 79-96.
43. Tunctan, B.; Ozveren, E.; Korkmaz, B.; Buharalioglu, C.K.; Tamer, L.; Degirmenci, U.; Atik, U. Nitric oxide reverses endotoxininduced inflammatory hyperalgesia via inhibition of prostacyclin production in mice. Pharmacol. Res., 2006, 53, 177-192.
44. Hardeland, R.; Tan, D.-X.; Reiter, R.J. Kynuramines, metabolites of melatonin and other indoles: the resurrection of an almost forgotten class of biogenic amines. J. Pineal Res., 2009, 47, 109-126.
45. Hardeland, R. Melatonin and its metabolites as anti-nitrosating and anti-nitrating agents. J. Exp. Integ. Med., 2011, 1, 67-81.
46. Jang, S.W.; Liu, X.; Pradoldej, S.; Tosini, G.; Chang, Q.; Iuvone, P.M.; Ye, K. N-acetylserotonin activates TrkB receptor in a circadian rhythm. Proc. Natl. Acad. Sci. USA, 2010, 107, 3876-3881.
47. Uz, T.; Qu, T.; Sugaya, K.; Manev, H. Neuronal expression of arylalkylamine N-acetyltransferase (AANAT) mRNA in the rat brain. Neurosci. Res., 2002, 42, 309-316.
48. Uz, T.; Ahmed, R.; Akhisaroglu, M.; Kurtuncu, M.; Imbesi, M.; Dirim Arslan, A.; Manev, H. Effect of fluoxetine and cocaine on the expression of clock genes in the mouse hippocampus and striatum. Neuroscience, 2005, 134, 1309-1316.
49. Sallanon, M.; Claustrat, B.; Touret, M. Presence of melatonin in various cat brainstem nuclei determined by radioimmunoassay. Acta Endocrinol. (Copenh.), 1982, 101, 161-165.
50. Pang, S.F.; Brown, G.M. Regional concentrations of melatonin in the rat brain in the light and dark period. Life Sci., 1983, 33, 1199-1204.
51. Kvetnoy, I.M. Extrapineal melatonin: location and role within diffuse neuroendocrine system. Histochem. J., 1999, 31, 1-12.
52. Lahiri, D.K., Ge, Y.-W., Sharman. E.H., Bondy, S.C. Age-related changes in serum melatonin in mice: higher levels of combined melatonin and 6-hydroxymelatonin sulfate in the cerebral cortex than serum, heart, liver and kidney tissues. J. Pineal Res., 2004, 36, 217-223.
53. Matsubara, E., Bryant-Thomas, T., Pacheco Quinto, J., Henry, T.L., Poeggeler, B., Herbert, D., Cruz-Sanchez, F., Chyan, Y.-J., Smith, M.A., Perry, G., Shoji, M., Abe, K., Leone, A., Grundke-Ikbal, I., Wilson, G.L., Ghiso, J., Williams, C., Refolo, L.M., Pappolla, M.A., Chain, D.G., Neria, E. Melatonin increases survival and inhibits oxidative and amyloid pathology in a transgenic model of Alzheimer's disease. J. Neurochem., 2003, 85, 1101-1108.
54. Liu, Y.-J.; Zhuang, J.; Zhu, H.-Y.; Shen, Y.-X.; Tan, Z.-L.; Zhou, J.-N. Cultured rat cortical astrocytes synthesize melatonin: absence of a diurnal rhythm. J. Pineal Res., 2007, 43, 232-238.
55. Liu, Y.-J.; Meng F.-T.; Wang, L.-L.; Zhang, L.-F.; Cheng, X.-P.; Zhou, J.-N. Apolipoprotein E influences melatonin biosynthesis by regulating NAT and MAOA expression in C6 cells. J. Pineal Res., 2012, 52, 397-402.
56. Biesalski, H.K.; Welker, H.A.; Thalmann, R.; Vollrath, L. Melatonin and other serotonin derivatives in the guinea pig membranous cochlea. Neurosci. Lett., 1988, 91, 41-46.
57. Lopez-Gonzalez, M.A.; Guerrero, J.M.; Delgado, F. Presence of the pineal hormone melatonin in rat cochlea: its variations with lighting conditions. Neurosci. Lett., 1997, 238, 81-83.
58. Zeman, M.; Józsa, R.; Cornélissen, G.; Stebelova, K.; Bubenik, G.,; Oláh, A.: Poeggeler, B.; Huether, G.; Hardeland, R.; Nagy, G.; Czernus, V.; Pan, W.; Otsuka, K.; Halberg, F. Chronomics: Circadian lead of extrapineal vs. pineal melatonin rhythms with an infradian hypothalamic exploration. Biomed. Pharmacother., 2005, 59, S213-S219.
59. Reppert, S.M.; Weaver, D.R.; Ebisawa, T. Cloning and characterization of a mammalian melatonin receptor that mediates reproductive and circadian responses. Neuron, 1994, 13, 1177-1185.
60. 1b melatonin receptor. Proc. Natl. Acad. Sci. U.S. A, 1995, 92, 8734-8738.
61. 2 receptor agonist. Neuropharmacology, 2005, 48, 301-310.
62. 1 melatonin receptor. J. Biol. Chem., 2008, 283, 16762-16771.
63. Dufourny, L.; Levasseur, A.; Migaud, M.; Callebaut, I.; Pontarotti, P.; Malpaux, B.; Monget, P. GPR50 is the mammalian ortholog of Mel1c: evidence of rapid evolution in mammals. BMC Evol. Biol., 2008, 8, 105.
64. Reppert, S.M.; Weaver, D.R.; Ebisawa, T.; Mahle, C.D.; Kolakowski, L.F., Jr. Cloning of a melatonin-related receptor from human pituitary. FEBS Lett., 1996, 386, 219-224.
65. 1 melatonin receptor function through heterodimerization. EMBO J., 2006, 25, 3012-3023.
66. Grünewald, E.; Kinnell, H.L.; Porteous, D.J.; Thomson, P.A. GPR50 interacts with neuronal NOGO-A and affects neurite outgrowth. Mol. Cell. Neurosci., 2009, 42, 363-371.
67. Li, J.; Hand, L, E.; Meng, Q.J.; Loudon, A.S.; Bechtold, D.A. GPR50 interacts with TIP60 to modulate glucocorticoid receptor signalling. PLoS One, 2011, 6, e23725.
68. 2 homodimers. Mol. Pharmacol., 2004, 66, 312-321.
69. McArthur, A.J.; Hunt, E.A.; Gillette, M.U. Melatonin action and signal transduction in the rat suprachiasmatic circadian clock: Activation of protein kinase C at dusk and dawn. Endocrinology, 1997, 138, 627-634.
70. 2 melatonin receptors in rat suprachiasmatic nucleus phase advances the circadian clock. Am. J. Physiol., 2001, 280, C110-C118.
71. 2 melatonin receptors in mammals. Endocrine, 2005, 27, 101-110.
72. Hardeland, R.; Coto-Montes, A. New vistas on oxidative damage and aging. Open Biol. J., 2010, 3, 39-52.
73. Nosjean, O.; Ferro, M.; Cogé, F.; Beauverger, P.; Henlin, J.M.; Lefoulon, F.; Fauchère, J.L.; Delagrange, P.; Canet, E.; Boutin, J.A. Identification of the melatonin-binding site MT3 as the quinone reductase 2. J. Biol. Chem., 2000, 275, 31311-31317.
74. Nosjean, O.; Nicolas, J.P.; Klupsch, F.; Delagrange, P.; Canet, E.; Boutin, J.A. Comparative pharmacological studies of melatonin receptors: MT1, MT2 and MT3/QR2. Tissue distribution of MT3/QR2. Biochem. Pharmacol., 2001, 61, 1369-1379.
75. 3 binding site on the NRH:quinone oxidoreductase 2 enzyme. Biochem. Pharmacol., 2005, 71, 74-88.
76. Carlberg, C.; Wiesenberg, I. The orphan receptor family RZR/ROR, melatonin and 5-lipoxygenase: an unexpected relationship. J. Pineal Res., 1995, 18, 171-178.
77. Carlberg, C. Gene regulation by melatonin. Ann. N.Y. Acad. Sci., 2000, 917, 387-396.
78. Carrillo-Vico, A.; Guerrero, J.M.; Lardone, P.J.; Reiter, R.J. A review of the multiple actions of melatonin on the immune system. Endocrine, 2005, 27, 189-200.
79. Weaver, D.R.; Reppert, S.M. The Mel1a melatonin receptor gene is expressed in human suprachiasmatic nuclei. Neuroreport, 1996, 8, 109-112.
80. 1 with vasopressin, oxytocin, and corticotropin-releasing hormone. J. Comp. Neurol., 2006, 499, 897-910.
81. 1 melatonin receptor expression in the suprachiasmatic nucleus in aging and Alzheimer's disease. Neurobiol. Aging, 2007, 28, 1239-1247.
82. Kalsbeek, A.; Palm, I.F.; La Fleur, S.E.; Scheer, F.A.; Perreau-Lenz, S.; Ruiter, M.; Kreier, F.; Cailotto, C.; Buijs, R.M. SCN outputs and the hypothalamic balance of life. J. Biol. Rhythms, 2006, 21, 458-469.
83. Kalsbeek, A.; Fliers, E.; Hofman, M.A.; Swaab, D.F.; Buijs, R.M. Vasopressin and the output of the hypothalamic biological clock. J. Neuroendocrinol., 2010, 22, 362-382.
84. Wu, Y.H.; Swaab, D.F. Disturbance and strategies for reactivation of the circadian rhythm system in aging and Alzheimer's disease. Sleep Med., 2007, 8, 623-636.
85. Hardeland, R. Investigational melatonin receptor agonists. Expert Opin. Investig. Drugs, 2010, 19, 747-764.
86. Liu, C.; Weaver, D.R.; Jin, X.; Shearman, L.P.; Pieschl, R.L.; Gribkoff, V.K.; Reppert, S.M. Molecular dissection of two distinct actions of melatonin on the suprachiasmatic circadian clock. Neuron, 1997, 19, 91-102.
87. von Gall, C.; Stehle, J.H.; Weaver, D.R. Mammalian melatonin receptors: molecular biology and signal transduction. Cell Tissue Res., 2002, 309, 151-162.
88. Dubocovich, M.L. Melatonin receptors: Role on sleep and circadian rhythm regulation. Sleep Med., 2007, 8, Suppl. 3, 34-42.
89. Lewy, A.J.; Ahmed, S.; Jackson, J.M.; Sack, R.L. Melatonin shifts human circadian rhythms according to a phase-response curve. Chronobiol. Int., 1992, 9, 380-392.
90. Burgess, H.J.; Revell, V.L.; and Eastman, C.I. A three pulse phase response curve to three milligrams of melatonin in humans. J. Physiol., 2008, 586, 639-647.
91. Weaver, D.R.; Liu, C.; Reppert, S.M. Nature's knockout: the Mel1b receptor is not necessary for reproductive and circadian responses to melatonin in Siberian hamsters. Mol. Endocrinol., 1996, 10, 1478-1487.
92. Pandi-Perumal, S.R.; Trakht, I.; Srinivasan, V.; Spence, D.W.; Maestroni, G.J.M.; Zisapel, N.; Cardinali, D.P. Physiological effects of melatonin: role of melatonin receptors and signal transduction pathways. Prog. Neurobiol., 2008, 185, 335-353.
93. 2 receptor. Br. J. Pharmacol., 2009, 158, 1248-1262.
94. 2 are decreased in Alzheimer's disease. Eur. J. Histochem., 2006, 50, 311-316.
95. Mazzucchelli, C.; Pannacci, M.; Nonno, R.; Lucini, V.; Fraschini, F.; Stankov, B.M. The melatonin receptor in the human brain: cloning experiments and distribution studies. Brain Res. Mol. Brain Res., 1996, 39, 117-126.
96. Ambriz-Tututi, M.; Rocha-González, H.I.; Cruz, S.L.; Granados-Soto, V. Melatonin: a hormone that modulates pain. Life Sci., 2009, 84, 489-498.
97. Al Ghoul, W.M.; Herman, M.D.; Dubocovich, M.L. Melatonin receptor subtype expression in human cerebellum. Neuroreport, 1998, 9, 4063-4068.
98. Adi, N.; Mash, D.C.; Ali, Y.; Singer, C.; Shehadeh, L.; Papapetropoulos, S. Melatonin MT1 and MT2 receptor expression in Parkinson's disease. Med. Sci. Monit., 2010, 16, BR61-BR67.
99. Savaskan, E.; Olivieri, G.; Meier, F.; Brydon, L.; Jockers, R.; Ravid, R.; Wirz-Justice, A.; Müller-Spahn, F. Increased melatonin 1a-receptor immunoreactivity in the hippocampus of Alzheimer's disease patients. J. Pineal Res., 2002, 32, 59-62.
100. 2 melatonin receptor expression in Alzheimer's disease. J. Pineal Res., 2005, 38, 10-16.
101. Meyer, P.; Pache, M.; Loeffler, K.U.; Brydon, L.; Jockers, R.; Flammer, J.; Wirz-Justice, A.; Savaskan, E. Melatonin MT-1-receptor immunoreactivity in the human eye. Br. J. Ophthalmol., 2002, 86, 1053-1057.
102. Savaskan, E.; Wirz-Justice, A.; Olivieri, G.; Pache, M.; Kräuchi, K.; Brydon, L.; Jockers, R.; Müller-Spahn, F.; Meyer, P. Distribution of melatonin MT1 receptor immunoreactivity in human retina. J. Histochem. Cytochem., 2002, 50, 519-526.
103. 1 melatonin receptor in the human retina: expression and localization. Invest. Ophthalmol. Vis. Sci., 2002, 43, 889-897.
104. 1 melatonin receptor in human and macaque retina. Exp. Eye Res., 2003, 77, 375-382.
105. 2 melatonin receptor subtype is present in human retina and decreases in Alzheimer's disease. Curr. Alzheimer Res., 2007, 4, 47-51.
106. Becker-André, M.; Wiesenberg, I.; Schaeren-Wiemers, N.; André, E.; Missbach, M.; Saurat, J.H.; Carlberg, C. Pineal gland hormone melatonin binds and activates an orphan of the nuclear receptor superfamily. J. Biol. Chem., 1994, 269, 28531-28534.
107. Baler, R.; Coon, S.; Klein, D.C. Orphan nuclear receptor RZRμ: cyclic AMP regulates expression in the pineal gland. Biochem. Biophys. Res. Commun., 1996, 220, 975-978.
108. Greiner, E.F.; Kirfel, J.; Greschik, H.; Dörflinger, U.; Becker, P.; Mercep, A.; Schüle, R. Functional analysis of retinoid Z receptor μ, a brain-specific nuclear orphan receptor. Proc. Natl. Acad. Sci. USA, 1996, 93, 10105-10110.
109. Park, H.T.; Baek, S.Y.; Kim, B.S.; Kim, J.B.; Kim, J.J. Developmental expression of 'RZR μ, a putative nuclear-melatonin receptor' mRNA in the suprachiasmatic nucleus of the rat. Neurosci. Lett., 1996, 217, 17-20.
110. Park, H.T.; Kim, Y.J.; Yoon, S.; Kim, J.B.; Kim, J.J. Distributional characteristics of the mRNA for retinoid Z receptor μ (RZR μ), a putative nuclear melatonin receptor, in the rat brain and spinal cord. Brain Res., 1997, 747, 332-337.
111. Schaeren-Wiemers, N.; André, E.; Kapfhammer, J.P.; Becker-André, M. The expression pattern of the orphan nuclear receptor RORbeta in the developing and adult rat nervous system suggests a role in the processing of sensory information and in circadian rhythm. Eur. J. Neurosci., 1997, 9, 2687-2701.
112. André, E.; Gawlas, K.; Becker-André, M. A novel isoform of the orphan nuclear receptor RORμ is specifically expressed in pineal gland and retina. Gene, 1998, 216, 277-283.
113. Sumi, Y.; Yagita, K.; Yamaguchi, S.; Ishida, Y.; Kuroda, Y.; Okamura, H. Rhythmic expression of RORμ mRNA in the mice suprachiasmatic nucleus. Neurosci. Lett., 2002, 320, 13-16.
114. André, E.; Conquet, F.; Steinmayr, M.; Stratton, S.C.; Porciatti, V.; Becker-André, M. Disruption of retinoid-related orphan receptor μ changes circadian behavior, causes retinal degeneration and leads to vacillans phenotype in mice. EMBO J., 1998, 17, 3867-3877.
115. Masana, M.I.; Sumaya, I.C.; Becker-André, M.; Dubocovich, M.L. Behavioral characterization and modulation of circadian rhythms by light and melatonin in C3H/HeN mice homozygous for the RORμ knockout. Am. J. Physiol. Regul. Integr. Comp. Physiol., 2007, 292, R2357-R2367.
116. Pévet, P.; Bothorel, B.; Slotten, H.; Saboureau, M. The chronobiotic properties of melatonin. Cell Tissue Res., 2002, 309, 183-191.
117. Stehle, J.H.; von Gall, C.; Korf, H.W. Melatonin: a clock-output, a clock-input. J. Neuroendocrinol., 2003, 15, 383-389.
118. Arendt, J.; Skene, D.J. Melatonin as a chronobiotic. Sleep Med. Rev., 2005, 9, 25-39.
119. Challet, E. Minireview: Entrainment of the suprachiasmatic clockwork in diurnal and nocturnal mammals. Endocrinology, 2007, 148, 5648-5655.
120. Dubocovich, M.L.; Rivera-Bermúdez, M.A.; Gerdin, M.J.; Masana, M.I. Molecular pharmacology, regulation and function of mammalian melatonin receptors. Front. Biosci., 2003, 8, d1093-d1108.
121. Silver, R.; Schwartz, W.J. The suprachiasmatic nucleus is a functionally heterogeneous timekeeping organ. Methods Enzymol., 2005, 393, 451-465.
122. Belle, M.D.; Diekman, C.O.; Forger, D.B.; Piggins, H.D. Daily electrical silencing in the mammalian circadian clock. Science, 2009, 326, 281-284.
123. de la Iglesia, H.O.; Cambras, T.; Schwartz, W.J.; Díez-Noguera, A. Forced desynchronization of dual circadian oscillators within the rat suprachiasmatic nucleus. Curr, Biol., 2004, 14, 796-800.
124. Agez, L.; Laurent, V.; Guerrero, H.Y.; Pévet, P.; Masson-Pévet, M.; Gauer, F. Endogenous melatonin provides an effective circadian message to both the suprachiasmatic nuclei and the pars tuberalis of the rat. J. Pineal Res., 2009, 46, 95-105.
125. Dinet, V.; Ansari, N.; Torres-Farfan, C.; Korf, H.W. Clock gene expression in the retina of melatonin-proficient (C3H) and melatonin-deficient (C57BL) mice. J. Pineal Res., 2007, 42, 83-91.
126. Dinet, V.; Korf, H.W. Impact of melatonin receptors on pCREB and clock-gene protein levels in the murine retina. Cell Tissue Res., 2007, 330, 29-34.
127. Saper, C.B.; Scammell, T.E.; Lu, J. Hypothalamic regulation of sleep and circadian rhythms. Nature, 2005, 437, 1257-1263.
128. Fuller, P.M.; Gooley, J.J.; Saper, C.B. Neurobiology of the sleepwake cycle: sleep architecture, circadian regulation, and regulatory feedback. J. Biol. Rhythms, 2006, 21, 482-493.
129. Dijk, D.J.; Roth, C.; Landolt, H.P.; Werth, E.; Aeppli, M.; Achermann, P.; Borbély, A.A. Melatonin effect on daytime sleep in men: suppression of EEG low frequency activity and enhancement of spindle frequency activity. Neurosci. Lett., 1995, 201, 13-16.
130. De Gennaro, L.; Ferrara, M. Sleep spindles: an overview. Sleep Med. Rev., 2003, 7, 423-440.
131. Jan, J.E.; Reiter, R.J.; Wasdell, M.B.; Bax, M. The role of the thalamus in sleep, pineal melatonin production, and circadian rhythm sleep disorders. J. Pineal Res., 2009, 46, 1-7.
132. Muñoz-Hoyos, A.; Sánchez-Forte, M.; Molina-Carballo, A.; Escames, G.; Martin-Medina, E.; Reiter, R.J.; Molina-Font, J.A.; Acuña-Castroviejo, D. Melatonin's role as an anticonvulsant and neuronal protector: experimental and clinical evidence. J. Child Neurol., 1998, 13, 501-509.
133. Molina-Carballo, A.; Muñoz-Hoyos, A.; Sánchez-Forte, M.; Uberos-Fernández, J.; Moreno-Madrid, F.; Acuña-Castroviejo, D. Melatonin increases following convulsive seizures may be related to its anticonvulsant properties at physiological concentrations. Neuropediatrics, 2007, 38, 122-125.
134. C receptors. J. Neurophysiol., 2005, 94, 968-978.
135. Prada, C.; Udin, S.B. Melatonin decreases calcium levels in retinotectal axons of Xenopus laevis by indirect activation of group III metabotropic glutamate receptors. Brain Res., 2005, 1053, 67-76.
136. León, J.; Vives, F.; Crespo, E.; Camacho, E.; Espinosa, A.; Gallo, M.A.; Escames, G.; Acuña-Castroviejo, D. Modification of nitric oxide synthase activity and neuronal response in rat striatum by melatonin and kynurenine derivatives. J. Neuroendocrinol., 1998, 10, 297-302.
137. León, J.; Macías, M.; Escames, G.; Camacho; E.; Khaldy, H.; Martín, M.; Espinosa, A.; Gallo, M.A.; Acuña-Castroviejo, D. Structure-related inhibition of calmodulin-dependent neuronal nitric-oxide synthase activity by melatonin and synthetic kynurenines. Mol. Pharmacol., 2000, 58, 967-975.
138. León, J.; Escames, G.; Rodríguez, M.I.; López, L.C.; Tapias, V.; Entrena, A.; Camacho, E.; Carrión, M.D.; Gallo, M.A.; Espinosa, A.; Tan, D.-X.; Reiter, R.J.; Acuña-Castroviejo, D. Inhibition of neuronal nitric oxide synthase activity by N1-acetyl-5-methoxykynuramine, a brain metabolite of melatonin. J. Neurochem., 2006, 98, 2023-2033.
139. + current mediates the migration of rat cerebellar granule cells stimulated by melatonin. J. Neurochem., 2007, 102, 333-344.
140. Zhang, M.; Cao, L.H.; Yang, X.L. Melatonin modulates glycine currents of retinal ganglion cells in rat. Neuroreport, 2007, 18, 1675-1678.
141. Hardeland, R. Antioxidative protection by melatonin: multiplicity of mechanisms from radical detoxification to radical avoidance. Endocrine, 2005, 27, 119-130.
142. Golombek, D.A.; Escolar, E.; Burin, L.J.; De Brito Sánchez, M.G.; Fernández Duque, D.; Cardinali, D.P. Chronopharmacology of melatonin: inhibition by benzodiazepine antagonism. Chronobiol. Int., 1992, 9, 124-131.
143. Golombek, D.A.; Fernández Duque, D.; De Brito Sánchez, M.G.; Burin, L.; Cardinali, D.P. Time-dependent anticonvulsant activity of melatonin in hamsters. Eur. J. Pharmacol., 1992, 210, 253-258.
144. Golombek, D.A.; Pévet, P.; Cardinali, D.P. Melatonin effects on behavior: possible mediation by the central GABAergic system. Neurosci. Biobehav. Rev., 1996, 20, 403-412.
145. Solmaz, I.; Gürkanlar, D.; Gökçil, Z.; Göksoy, C.; Ozkan, M.; Erdoan, E. Antiepileptic activity of melatonin in guinea pigs with pentylenetetrazol-induced seizures. Neurol. Res., 2009, 31, 989-995.
146. Cardinali, D.P.; Pandi-Perumal, S.R.; Niles, L.P. Melatonin and its receptors: Biological function in circadian sleep-wake regulation. In: Neurochemistry of Sleep and Wakefulness; Monti, J.M.; Pandi-Perumal, S.R.; Sinton, C.M. Eds.; Cambridge University Press: Cambridge, UK, 2008, pp. 283-314.
147. Fenoglio-Simeone, K.; Mazarati, A.; Sefidvash-Hockley, S.; Shin, D.; Wilke, J.; Milligan, H.; Sankar, R.; Rho, J.M.; Maganti, R. Anticonvulsant effects of the selective melatonin receptor agonist ramelteon. Epilepsy Behav., 2009, 16, 52-57.
148. Golombek, D.A.; Escolar, E.; Burin, L.J.; De Brito Sánchez, M.G.; Cardinali, D.P. Time-dependent melatonin analgesia in mice: inhibition by opiate or benzodiazepine antagonism. Eur. J. Pharmacol., 1991, 194, 25-30.
149. Golombek, D.A.; Escolar, E.; Cardinali, D.P. Melatonin-induced depression of locomotor activity in hamsters: time dependency and inhibition by the central type benzodiazepine antagonist Ro 15-1788. Physiol. Behav., 1991, 49, 1091-1098.
150. Golombek, D.A.; Martíni, M.; Cardinali, D.P. Melatonin as an anxiolytic in rats: time dependence and interaction with the central GABAergic system. Eur. J. Pharmacol., 1993, 237, 231-236.
151. Papp, M.; Litwa, E.; Gruca, P.; Mocaër, E. Anxiolytic-like activity of agomelatine and melatonin in three animal models of anxiety. Behav. Pharmacol., 2006, 17, 9-18.
152. Ulugol, A.; Dokmeci, D.; Guray, G.; Sapolyo, N.; Ozyigit, F.; Tamer, M. Antihyperalgesic, but not antiallodynic, effect of melatonin in nerve-injured neuropathic mice: Possible involvements of the L-arginine-NO pathway and opioid system. Life Sci., 2006, 78, 1592-1597.
153. Srinivasan, V.; Pandi-Perumal, S.R.; Spence, D.W.; Moscovitch, A.; Trakht, I.; Brown, G.M.; Cardinali, D.P. Potential use of melatonergic drugs in analgesia: Mechanisms of action. Brain Res. Bull., 2010, 81, 362-371.
154. 2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways. J. Pharmacol. Exp. Ther., 2003, 306, 954-964.
155. Dubocovich, M.L. Characterization of a retinal melatonin receptor. J. Pharmacol. Exp. Ther., 1985, 234, 395-401.
156. Ekmekcioglu, C. Melatonin receptors in humans: biological role and clinical relevance. Biomed. Pharmacother., 2006, 60, 97-108.
157. Sengupta, A.; Baba, K.; Mazzoni, F.; Pozdeyev, N.V.; Strettoi, E.; Iuvone, P.M.; Tosini, G. Localization of melatonin receptor 1 in mouse retina and its role in the circadian regulation of the electroretinogram and dopamine levels. PLoS One, 2011, 6, e24483.
158. Ruan, G.X.; Allen, G.C.; Yamazaki, S.; McMahon, D.G. An autonomous circadian clock in the inner mouse retina regulated by dopamine and GABA. PLoS Biol., 2008, 6, e249.
159. Sakamoto, K.; Liu, C.; Kasamatsu, M.; Iuvone, P.M.; Tosini, G. Intraocular injection of kainic acid does not abolish the circadian rhythm of arylalkylamine N-acetyltransferase mRNA in rat photoreceptors. Mol. Vis., 2006, 12, 117-124.
160. Zawilska, J.B.; Nowak, J.Z. Dopamine D4-like receptors in vertebrate retina: does the retina offer a model for the D4-receptor analysis? Pol. J. Pharmacol., 1997, 49, 201-211.
161. Lavoie, J.; Gagné, A.M.; Lavoie, M.P.; Sasseville, A.; Charron, M.C.; Hébert, M. Circadian variation in the electroretinogram and the presence of central melatonin. Doc. Ophthalmol., 2010, 120, 265-272.
162. Zisapel, N.; Laudon, M. Dopamine release induced by electrical field stimulation of rat hypothalamus in vitro: inhibition by melatonin. Biochem. Biophys. Res. Commun., 1982, 104, 1610-1616.
163. 1 in the central dopaminergic system. Brain Res. Mol. Brain Res., 2005, 136, 45-53.
164. Willis, G.L. Parkinson's disease as a neuroendocrine disorder of circadian function: dopamine-melatonin imbalance and the visual system in the genesis and progression of the degenerative process. Rev. Neurosci., 2008, 19, 245-316.
165. Régrigny, O.; Delagrange, P.; Scalbert, E.; Atkinson, J.; Lartaud-Idjouadiene, I. Melatonin improves cerebral circulation security margin in rats. Am. J. Physiol., 1998, 275, H139-H144.
166. Webster, N.J.; Pirrung, M.C. Small molecule activators of the Trk receptors for neuroprotection. BMC Neurosci., 2008, 9 Suppl. 2, S1.
167. Saragovi, H.U.; Hamel, E.; Di Polo, A. A neurotrophic rationale for the therapy of neurodegenerative disorders. Curr. Alzheimer Res., 2009, 6, 419-423.
168. Kidd, P.M. Integrated brain restoration after ischemic stroke medical management, risk factors, nutrients, and other interventions for managing inflammation and enhancing brain plasticity. Altern. Med. Rev., 2009, 14, 14-35.
169. Sharma, R.; McMillan, C.R.; Tenn, C.C.; Niles, L.P. Physiological neuroprotection by melatonin in a 6-hydroxydopamine model of Parkinson's disease. Brain Res., 2006, 1068, 230-236.
170. Olivieri, G.; Otten, U.; Meier, F.; Baysang, G.; Dimitriades-Schmutz, B.; Müller-Spahn, F.; Savaskan, E. β-Amyloid modulates tyrosine kinase B receptor expression in SHSY5Y neuroblastoma cells: influence of the antioxidant melatonin. Neuroscience, 2003, 120, 659-665.
171. Tasset, I.; Agüera, E.; Olmo-Camacho, R.; Escribano, B.; Sánchez-López, F.; Delgado, M.J.; Cruz, A.H.; Gascón, F.; Luque, E.; Peña, J.; Jimena, I.M.; Túnez, I. Melatonin improves 3-nitropropionic acid induced behavioral alterations and neurotrophic factors levels. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2011, 35, 1944-1949.
172. Tang, Y.P.; Ma, Y.L.; Chao, C.C.; Chen, K.Y.; Lee, E.H. Enhanced glial cell line-derived neurotrophic factor mRNA expression upon (-)-deprenyl and melatonin treatments. J. Neurosci. Res., 1998, 53, 593-604.
173. Kong, P.J.; Byun, J.S.; Lim, S.Y.; Lee, J.J.; Hong, S.J.; Kwon, K.J.; Kim, S.S. Melatonin induces Akt phosphorylation through melatonin receptor-and PI3K-dependent pathways in primary astrocytes. Korean J. Physiol. Pharmacol., 2008, 12, 37-41.
174. Armstrong, K.J.; Niles, L.P. Induction of GDNF mRNA expression by melatonin in rat C6 glioma cells. Neuroreport, 2002, 13, 473-475.
175. Chen, K.B.; Lin, A.M.; Chiu, T.H. Oxidative injury to the locus coeruleus of rat brain: neuroprotection by melatonin. J. Pineal Res., 2003, 35, 109-117.
176. Lee, S.H.; Chun, W.; Kong, P.J.; Han, J.A.; Cho, B.P.; Kwon, O.Y.; Lee, H.J.; Kim, S.S. Sustained activation of Akt by melatonin contributes to the protection against kainic acid-induced neuronal death in hippocampus. J. Pineal Res., 2006, 40, 79-85.
177. 2 receptors and neurotrophic factors CDNF and MANF in the rat brain. Int. J. Neuropsychopharmacol., 2012 [Epub ahead of print, Jan 16; DOI: 10.1017/S1461145711001969].
178. Soumier, A.; Banasr, M.; Lortet, S.; Masmejean, F.; Bernard, N.; Kerkerian-Le-Goff, L.; Gabriel, C.; Millan, M.J.; Mocaer, E.; Daszuta, A. Mechanisms contributing to the phase-dependent regulation of neurogenesis by the novel antidepressant, agomelatine, in the adult rat hippocampus. Neuropsychopharmacology, 2009, 34, 2390-2403.
179. Molteni, R.; Calabrese, F.; Pisoni, S.; Gabriel, C.; Mocaer, E.; Racagni, G.; Riva, M.A. Synergistic mechanisms in the modulation of the neurotrophin BDNF in the rat prefrontal cortex following acute agomelatine administration. World J. Biol. Psychiatry, 2010, 11, 148-153.
180. Païzanis, E.; Renoir, T.; Lelievre, V.; Saurini, F.; Melfort, M.; Gabriel, C.; Barden, N.; Mocaër, E.; Hamon, M.; Lanfumey, L. Behavioural and neuroplastic effects of the new-generation antidepressant agomelatine compared to fluoxetine in glucocorticoid receptor-impaired mice. Int. J. Neuropsychopharmacol., 2010, 13, 759-774.
181. 2C receptors. World J. Biol. Psychiatry, 2011, 12, 574-587.
182. Imbesi, M.; Uz, T.; Dzitoyeva, S.; Manev, H. Stimulatory effects of a melatonin receptor agonist, ramelteon, on BDNF in mouse cerebellar granule cells. Neurosci. Lett., 2008, 439, 34-36.
183. Imbesi, M.; Uz, T.; Manev, H. Role of melatonin receptors in the effects of melatonin on BDNF and neuroprotection in mouse cerebellar neurons. J. Neural Transm., 2008, 115, 1495-1499.
184. Olivieri, G.; Otten, U.; Meier, F.; Baysang, G.; Dimitriades-Schmutz, B.; Müller-Spahn, F.; Savaskan, E. Oxidative stress modulates tyrosine kinase receptor A and p75 receptor (low-affinity nerve growth factor receptor) expression in SHSY5Y neuroblastoma cells. Neurol. Clin. Neurophysiol., 2002, 2002, 2-10.
185. Kong, X.; Li, X.; Cai, Z.; Yang, N.; Liu, Y.; Shu, J.; Pan, L.; Zuo, P. Melatonin regulates the viability and differentiation of rat midbrain neural stem cells. Cell. Mol. Neurobiol., 2008, 28, 569-579.
186. Niles, L.P.; Armstrong, K.J.; Rincón Castro, L.M.; Dao, C.V.; Sharma, R.; McMillan, C.R.; Doering, L.C.; Kirkham, D.L. Neural stem cells express melatonin receptors and neurotrophic factors: colocalization of the MT1 receptor with neuronal and glial markers. BMC Neurosci., 2004, 5, 41.
187. Sharma, R.; Ottenhof, T.; Rzeczkowska, P.A.; Niles, L.P. Epigenetic targets for melatonin: induction of histone H3 hyperacetylation and gene expression in C17.2 neural stem cells. J. Pineal Res., 2008, 45, 277-284.
188. Reiter, R.J. Oxidative damage in the central nervous system: protection by melatonin. Prog. Neurobiol., 1998, 56, 359-384.
189. Reiter, R.J.; Cabrera, J.; Sainz, R.M.; Mayo, J.C.; Manchester, L.C.; Tan, D.-X. Melatonin as a pharmacological agent against neuronal loss in experimental models of Huntington's disease, Alzheimer's disease and parkinsonism. Ann. N.Y. Acad. Sci., 1999, 890, 471-485.
190. Pappolla, M.A.; Chyan, Y.J.; Poeggeler, B.; Frangione, B.; Wilson, G.; Ghiso, J.; Reiter, R.J. An assessment of the antioxidant and the antiamyloidogenic properties of melatonin: implications for Alzheimer's disease. J. Neural. Transm., 2000, 107, 203-231.
191. Reiter, R.J.; Acuña-Castroviejo, D.; Tan, D.-X.; Burkhardt, S. Free radical-mediated molecular damage. Mechanisms for the protective actions of melatonin in the central nervous system. Ann. N.Y. Acad. Sci., 2001, 939, 200-215.
192. Cuzzocrea, S.; Reiter, R.J. Pharmacological action of melatonin in shock, inflammation and ischemia/reperfusion injury. Eur. J. Pharmacol., 2001, 426, 1-10.
193. Hardeland, R.; Coto-Montes, A.; Poeggeler, B. Circadian rhythms, oxidative stress, and antioxidative defense mechanisms. Chronobiol. Int., 2003, 20, 921-962.
194. Reiter, R.J.; Sainz, R.M.; Lopez-Burillo, S.; Mayo, J.C.; Manchester, L.C.; Tan, D.-X. Melatonin ameliorates neurologic damage and neurophysiologic deficits in experimental models of stroke. Ann. N.Y. Acad. Sci., 2003, 993, 35-47.
195. Reiter, R.J.; Tan, D.-X.; Pappolla, M.A. Melatonin relieves the neural oxidative burden that contributes to dementias. Ann. N.Y. Acad. Sci., 2004, 1035, 179-196.
196. Tan, D.-X.; Manchester, L.C.; Sainz, R.M.; Mayo, J.C.; León, J.; Reiter, R.J. Physiological ischemia/reperfusion phenomena and their relation to endogenous melatonin production: a hypothesis. Endocrine, 2005, 27, 149-158.
197. Reiter, R.J.; Tan, D.-X.; Leon, J.; Kilic, U.; Kilic, E. When melatonin gets on your nerves: its beneficial actions in experimental models of stroke. Exp. Biol. Med. (Maywood), 2005, 230, 104-117.
198. Srinivasan, V.; Pandi-Perumal, S.R.; Maestroni, G.J.M.; Esquifino, A.I.; Hardeland, R.; Cardinali, D.P. Role of melatonin in neurodegenerative diseases. Neurotox. Res., 2005, 7, 293-318.
199. Srinivasan, V.; Pandi-Perumal, S.R.; Cardinali, D.P.; Poeggeler, B.; Hardeland, R. Melatonin in Alzheimer's disease and other neurodegenerative disorders. Behav. Brain Funct., 2006, 2, 15.
200. Maldonado, M.D.; Murillo-Cabezas, F.; Terron, M.P.; Flores, L.J.; Tan, D.-X.; Manchester, L.C.; Reiter, R.J. The potential of melatonin in reducing morbidity-mortality after craniocerebral trauma. J. Pineal Res., 2007, 42, 1-11.
201. Reiter, R.J.; Tan, D.-X.; Manchester, L.C.; Tamura, H. Melatonin defeats neurally-derived free radicals and reduces the associated neuromorphological and neurobehavioral damage. J. Physiol. Pharmacol., 2007, 58, Suppl. 6, 5-22.
202. Samantaray, S.; Das, A.; Thakore, N.P.; Matzelle, D.D.; Reiter, R, J.; Ray, S.K.; Banik, N.L. Therapeutic potential of melatonin in traumatic central nervous system injury. J. Pineal Res., 2009, 47, 134-142.
203. Hardeland, R. Neuroprotection by radical avoidance: search for suitable agents. Molecules, 2009, 14, 5054-5102.
204. Reiter, R.J.; Manchester, L.C.; Tan, D.-X. Neurotoxins: free radical mechanisms and melatonin protection. Curr. Neuropharmacol., 2010, 8, 194-210.
205. Rosales-Corral, S.A.; Acuña-Castroviejo, D.; Coto-Montes, A.; Boga, J.A.; Manchester, L.C.; Fuentes-Broto, L.; Korkmaz, A.; Ma, S.; Tan, D.-X.; Reiter, R.J. Alzheimer's disease: pathological mechanisms and the beneficial role of melatonin. J. Pineal Res., 2012, 52, 167-202.
206. Zhang, E.E.; Kay, S.A. Clocks not winding down: unravelling circadian networks. Nat. Rev. Mol. Cell Biol., 2010, 11, 764-776.
207. Teng, F.Y.; Hor, C.H.; Tang, B.L. Emerging cues mediating astroglia lineage restriction of progenitor cells in the injured/diseased adult CNS. Differentiation, 2009, 77, 121-127.
208. Shoba, B.; Lwin, Z.M.; Ling, L.S.; Bay, B.H.; Yip, G.W.; Kumar. S.D. Function of sirtuins in biological tissues. Anat. Rec. (Hoboken), 2009, 292, 536-543.
209. D'Mello, S.R. Histone deacetylases as targets for the treatment of human neurodegenerative diseases. Drug News Perspect., 2009, 22, 513-524.
210. Ramadori, G.; Coppari, R. Pharmacological manipulations of CNS sirtuins: potential effects on metabolic homeostasis. Pharmacol. Res., 2010, 62, 48-54.
211. Cen, Y.; Youn, D.Y.; Sauve, A.A. Advances in characterization of human sirtuin isoforms: chemistries, targets and therapeutic applications. Curr. Med. Chem., 2011, 18, 1919-1935.
212. Neri, C. Role and therapeutic potential of the pro-longevity factor FOXO and its regulators in neurodegenerative disease. Front. Pharmacol., 2012, 3, 15.
213. Asher, G.; Gatfield, D.; Stratmann, M.; Reinke, H.; Dibner, C.; Kreppel, F.; Mostoslavsky, R.; Alt, F.W.; Schibler, U. SIRT1 regulates circadian clock gene expression through PER2 deacetylation. Cell, 2008, 134, 317-328.
214. Belden, W.J.; Dunlap, J.C. SIRT1 is a circadian deacetylase for core clock components. Cell, 2008, 134, 212-214.
215. +-dependent deacetylase SIRT1 modulates CLOCK-mediated chromatin remodeling and circadian control. Cell, 2008, 134, 329-340.
216. Grimaldi, B.; Nakahata, Y.; Kaluzova M.; Masubuchi, S.; Sassone-Corsi, P. Chromatin remodeling, metabolism and circadian clocks: the interplay of CLOCK and SIRT1. Int. J. Biochem. Cell Biol., 2009, 41, 81-86.
217. Wijnen, H. Circadian rhythms. A circadian loop asSIRTs itself. Science, 2009, 324, 598-599.
218. + biosynthesis. Science, 2009, 324, 651-654.
219. + salvage pathway by CLOCKSIRT1. Science, 2009, 324, 654-657.
220. Hill, S.M.; Frasch, T.; Xiang S.; Yuan, L.; Duplessis, T.; Mao, L. Molecular mechanisms of melatonin anticancer effects. Integr. Cancer Ther., 2009, 8, 337-346.
221. Jung-Hynes, B.; Schmit, T.L.; Reagan-Shaw, S.R.; Siddiqui, I.A.; Mukhtar, H.; Ahmad, N. Melatonin, a novel Sirt1 inhibitor, imparts antiproliferative effects against prostate cancer in vitro in culture and in vivo in TRAMP model. J. Pineal Res., 2011, 50, 140-149.
222. Gutierrez-Cuesta, J.; Tajes, M.; Jiménez, A.; Coto-Montes, A.; Camins, A.; Pallàs, M. Evaluation of potential pro-survival pathways regulated by melatonin in a murine senescence model. J. Pineal Res., 2008, 45, 497-505.
223. Chang, H.M.; Wu, U.I.; Lan, C.T. Melatonin preserves longevity protein (sirtuin 1) expression in the hippocampus of total sleepdeprived rats. J. Pineal Res., 2009, 47, 211-220.
224. Tajes, M.; Gutierrez-Cuesta, J.; Ortuño-Sahagun, D.; Camins, A.; Pallàs, M. Anti-aging properties of melatonin in an in vitro murine senescence model: involvement of the sirtuin 1 pathway. J. Pineal Res., 2009, 47, 228-237.
225. Takahashi, S.; Inoue, I.; Nakajima, Y.; Seo, M.; Nakano, T.; Yang, F.; Kumagai, M.; Komoda, T.; Awata, T.; Ikeda, M.; Katayama, S. A promoter in the novel exon of hPPARα directs the circadian expression of PPARα. J. Atheroscler. Thromb., 2010, 17, 73-83.
226. Hardeland, R. Melatonin, mitochondrial electron flux and leakage: recent findings and resolution of contradictory results. Adv. Stud. Biol., 2009, 1, 207-230.
227. Kapoor, N.; Pant, A.B.; Dhawan, A.; Dwievedi, U.N.; Seth, P.K.; Parmar, D. Cytochrome P450 1A isoenzymes in brain cells: Expression and inducibility in cultured rat brain neuronal and glial cells. Life Sci., 2006, 79, 2387-2394.
228. Singh, S.; Singh, K.; Gupta, S.P.; Patel, D.K.; Singh, V.K.; Singh, R.K.; Singh, M.P. Effect of caffeine on the expression of cytochrome P450 1A2, adenosine A2A receptor and dopamine transporter in control and 1-methyl 4-phenyl 1,2,3,6-tetrahydropyridine treated mouse striatum. Brain Res., 2009, 1283, 115-126.
229. Nannelli, A.; Rossignolo, F.; Tolando, R.; Rossato, P.; Longo, V.; Gervasi, P.G. Effect of μ-naphthoflavone and AhR-regulated genes (CYP1A1, 1A2, 1B1, 2S1, Nrf2, and GST) and antioxidant enzymes in various brain regions of pig. Toxicology, 2009, 265, 69-79.
230. Ma, X.; Idle, J.R.; Krausz, K.W.; Gonzalez, F.J. Metabolism of melatonin by human cytochromes p450. Drug Metab. Dispos., 2005, 33, 489-494.
231. Isoherranen, N.; Lewy, R.H.; Yagen, B.; Woodhead, J.H.; White, H.S.; Bialer, M. Metabolism of a new antiepileptic drug, N-methyltetramethylcyclopropanecarboxamide, and anticonvulsant activity of its metabolites. Epilepsy Res., 2004, 58, 1-12.
232. Ishii, G.; Suzuki, A.; Oshino, S.; Shiraishi, H.; Otani, K. CYP2C19 polymorphism affects personality traits of Japanese females. Neurosci. Lett., 2007, 411, 77-80.
233. Yasui-Furukori, N.; Kaneda, A.; Iwashima, K.; Saito, M.; Tsuchimine, S.; Kaneko, S. Association between cytochrome P450 (CYP) 2C19 polymorphisms and harm avoidance in Japanese. Am. J. Genet. B Neuropsychiatr. Genet., 2007, 144B, 724-727.
234. Hirata, F.; Hayaishi, O.; Tokuyama, T.; Senoh, S. In vitro and in vivo formation of two new metabolites of melatonin. J. Biol. Chem., 1974, 249, 1311-1313.
235. Lahiri, D.K.; Ge, Y.-W.; Sharman. E.H.; Bondy, S.C. Age-related changes in serum melatonin in mice: higher levels of combined melatonin and 6-hydroxymelatonin sulfate in the cerebral cortex than serum, heart, liver and kidney tissues. J. Pineal Res., 2004, 36, 217-223.
236. Leston, J.; Harthé, C.; Brun, J.; Mottolese, C.; Mertens, P.; Sindou, M.; Claustrat, B. Melatonin is release in the third ventricle in humans. A study in movement disorders. Neurosci. Lett., 2009, 469, 294-297.
237. Salman, E.D.; Kadlubar, S.A.; Falany, C.N. Expression and localization of cytosolic sulfotransferase (SULT) 1A1 and SULT1A3 in normal human brain. Drug Metab. Dispos., 2009, 37, 706-709.
238. Akimov, M.G.; Nazimov, I.V.; Gretskaya, N.M.; Zinchenko, G.N.; Bezuglov, V.V. Sulfation of N-acyl dopamines in rat tissues. Biochemistry (Mosc.), 2009, 74, 681-685.
239. Takahashi, S.; Sakakibara, Y.; Mishiro, E.; Kouriki, H.; Nobe, R.; Kurogi, K.; Yasuda, S.; Liu, M.C.; Suiko, M. Molecular cloning, expression and characterization of a novel mouse SULT6 cytosolic sulfotransferase. J. Biochem., 2009, 146, 399-405.
240. Gibbs, T.T.; Russek, S.J.; Farb, D.H. Sulfated steroids as endogenous neuromodulators. Pharmacol. Biochem. Behav., 2006, 84, 555-567.
241. Oommen, A.; Balasubramanian, A.S. Aryl acylamidase of monkey brain and liver: response to inhibitors and relationship to acetylcholinesterase. Biochem. Pharmacol., 1978, 27, 891-895.
242. Oommen, A.; Balasubramanian, A.S. The association of serotoninsensitive aryl acylamidase with acetylcholinesterase in the monkey brain. Eur. J. Biochem., 1979, 94, 135-143.
243. George, S.T.; Balasubramanian, A.S. The identity of the serotoninsensitive aryl acylamidase with acetylcholinesterase from human erythrocytes, sheep basal ganglia and electric eel. Eur. J. Biochem., 1980, 111, 511-524.
244. Balasubramanian, A.S.; Bhanumathy, C.D. Noncholinergic functions of cholinesterases. FASEB J., 1993, 7, 1354-1358.
245. Masson, P.; Froment, M.T.; Darvesh, S.; Schopfer, L.M.; Lockridge, O. Aryl acylamidase activity of human serum albumin with o-nitrotrifluoroacetanilide as the substrate. J. Enzyme Inhib. Med. Chem., 2007, 22, 463-469.
246. Hsu, L.L. Pineal aryl acylamidase: effects of melatonin, serotoninrelated compounds, μ-carbolines, RO4-4602 and antidepressants. Res. Commun. Chem. Pathol. Pharmacol., 1984, 43, 223-234.
247. Cahill, G.M.; Besharse, J.C. Retinal melatonin is metabolized within the eye of Xenopus laevis. Proc. Natl. Acad. Sci. USA, 1989, 86, 1098-1102.
248. Grace, M.S.; Cahill, G.M.; Besharse, J.C. Melatonin deacetylation: retinal vertebrate class distribution and Xenopus laevis tissue distribution. Brain Res., 1991, 559, 56-63.
249. Grace, M.S.; Besharse, J.C. Solubilization and biochemical characterization of the melatonin deacetylase from Xenopus laevis retina. J. Neurochem., 1993, 60, 990-999.
250. Grace, M.S.; Besharse, J.C. Melatonin deacetylase activity in the pineal gland and brain of the lizards Anolis carolinensis and Sceloporus jarrovi. Neuroscience, 1994, 62, 615-623.
251. Li, P.; Pang, S, F.; Tsang, C.W. Retinal 5-methoxytryptamine and 5-methoxyindole-3-acetic acid in the rat and quail: diurnal rhythms and interspecies differences. Biochem. Biophys. Res. Commun., 1997, 239, 353-356.
252. Hsu, L.L.; Paul, S.M.; Halaris, A.E.; Freedman, D.X. Rat brain aryl acylamidase: multiple forms and inhibition effects of LSD, serotonin and related compounds. Life Sci., 1977, 20, 857-866.
253. Hardeland, R. Melatonin and 5-methoxytryptamine in nonmetazoans. Reprod. Nutr. Dev., 1999, 39, 399-408.
254. 125I]iodomelatonin binding site. J. Neurochem., 1995, 64, 1892-1895.
255. Mirmiran, M.; Pévet, P. Effects of melatonin and 5-methoxytryptamine on sleep-wake patterns in the male rat. J. Pineal Res., 1986, 3, 135-141.
256. Pévet, P.; Buijs, R.M.; Masson-Pévet, M. Effect of pinealectomy and a constant high level of circulating melatonin or of 5-methoxytryptamine on the vasopressinergic innervation in the brain of the European hamster (Cricetus cricetus, L). J. Neural Transm., 1987, 70, 287-294.
257. Eison, A.S.; Wright, R.N.; Freeman, R. Peripheral 5-carboxamidotryptamine induces hindlimb scratching by stimulating 5-HT1A receptors in rats. Life Sci., 1992, 51, PL95-PL99.
258. Roscetti, G.; Del Carmine, R.; Trabucchi, M.; Massotti, M.; Purdy, R.H.; Barbaccia, M.L. Modulation of neurosteroid synthesis/accumulation by L-ascorbic acid in rat brain tissue: inhibition by selected serotonin antagonists. J. Neurochem., 1998, 71, 1108-1117.
259. Sprenger, J.; Hardeland, R.; Fuhrberg, B.; Han S.-Z. Melatonin and other 5-methoxylated indoles in yeast: Presence in high concentrations and dependence on tryptophan availability. Cytologia, 1999, 64, 209-213.
260. Morton, D.J. Both hydroxy-and methoxyindoles modify basal temperature in the rat. J. Pineal Res., 1987, 4, 1-5.
261. Tan, D.-X.; Reiter, R.J.; Manchester, L.C.; Yan, M.T.; El-Sawi, M.; Sainz, R.M.; Mayo, J.C.; Kohen, R.; Allegra, M.; Hardeland, R. Chemical and physical properties and potential mechanisms: melatonin as a broad spectrum antioxidant and free radical scavenger. Curr. Top. Med. Chem., 2002, 2, 181-197.
262. Tan, D.-X.; Manchester, L.C.; Reiter, R.J.; Plummer, B.F.; Hardies, L.J.; Weintraub, S.T.; Vijayalaxmi; Shepherd, A.M. A novel melatonin metabolite, cyclic 3-hydroxymelatonin: a biomarker of in vivo hydroxyl radical generation. Biochem. Biophys. Res. Commun., 1998, 253, 614-620.
263. Tan, D.-X.; Hardeland, R.; Manchester, L.C.; Poeggeler, B.; Lopez-Burillo, S.; Mayo, J.C.; Sainz, R.M.; Reiter, R.J. Mechanistic and comparative studies of melatonin and classic antioxidants in terms of their interactions with the ABTS cation radical. J. Pineal Res., 2003, 34, 249-259.
264. 2-formyl-5-methoxykynuramine, a biogenic amine and melatonin metabolite, functions as a potent antioxidant. FASEB J., 2001, 15, 2294-2296.
265. Hardeland, R.; Poeggeler, B.; Niebergall, R.; Zelosko, V. Oxidation of melatonin by carbonate radicals and chemiluminescence emitted during pyrrole ring cleavage. J. Pineal Res., 2003, 34, 17-25.
266. Hardeland, R.; Ressmeyer, A.-R.; Zelosko, V.; Burkhardt, S.; Poeggeler, B. Metabolites of melatonin: Formation and properties of the methoxylated kynuramines AFMK and AMK. In: Recent Advances in Endocrinology and Reproduction: Evolutionary, Biotechnological and Clinical Applications; Haldar, C.; Singh, S.S. Eds.; Banaras Hindu University: Varanasi, 2004, pp. 21-38.
267. 2-formyl-5-methoxykynuramine. J. Pineal Res., 2008, 44, 450-455.
268. 1-acetyl-5-methoxykynuramine (AMK): scavenging of free radicals and prevention of protein destruction. Redox Rep., 2003, 8, 205-213.
269. 1-acetyl-5-methoxykynuramine (AMK) with the ABTS cation radical: identification of new oxidation products. Redox Rep., 2006, 11, 15-24.
270. 1-acetyl-5-methoxykynuramine is a potent singlet oxygen scavenger. J. Pineal Res., 2009, 46, 49-52.
271. 1-acetyl-5-methoxykynuramine (AMK) with the tyrosine side-chain fragment, 4-ethylphenol. Redox Rep., 2008, 13, 102-108.
272. 1-acetyl-5-methoxykynuramine) with reactive nitrogen species: Formation of novel compounds, 3-acetamidomethyl-6-methoxycinnolinone and 3-nitro-AMK. J. Pineal Res., 2005, 39, 251-260.
273. 1-acetyl-5-methoxykynuramine. J. Pineal Res., 2007, 43, 382-388.
274. Blanchard-Fillion, B.; Servy, C.; Ducrocq, C. 1-Nitrosomelatonin is a spontaneous NO-releasing compound. Free Radic. Res., 2001, 35, 857-866.
275. Peyrot, F.; Grillon, C.; Vergely, C.; Rochette, L.; Ducrocq, C. Pharmacokinetics of 1-nitrosomelatonin and detection by EPR using iron dithiocarbamate complex in mice. Biochem. J., 2005, 387, 473-478.
276. 1-nitrosomelatonin: nucleophilic attack versus reducing pathways. J. Org. Chem., 2005, 70, 5790-5798.
277. Rosen, J., Than, N.N.; Koch, D.; Poeggeler, B.; Laatsch, H.; Hardeland, R. Interactions of melatonin and its metabolites with the ABTS cation radical: extension of the radical scavenger cascade and formation of a novel class of oxidation products, C2-substituted 3-indolinones. J. Pineal Res., 2006, 41, 374-381.
278. Tan, D.-X.; Manchester, L.C.; Terron, M.P.; Flores, L.J.; Reiter, R.J. One molecule, many derivatives: a never-ending interaction of melatonin with reactive oxygen and nitrogen species? J. Pineal Res., 2007, 42, 28-42.
279. 1-acetyl-5-methoxy-kynuramine formation from melatonin in mice. J. Pineal Res., 2010, 49, 106-114.
280. 2-formyl-5-methoxykynuramine, in cerebrospinal fluid of patients with meningitis: a possible immunomodulatory mechanism. J. Pineal Res., 2005, 39, 302-306.
281. Mayo, J.C.; Sainz, R.M.; Tan, D.-X.; Hardeland, R.; Leon, J.; Rodriguez, C.; Reiter, R.J. Anti-inflammatory actions of melatonin and its metabolites, N1-acetyl-N2-formyl-5-methoxykynuramine (AFMK) and N1-acetyl-5-methoxykynuramine (AMK), in macrophages. J. Neuroimmunol., 2005, 165, 139-149.
282. Rivara, S.; Mor, M.; Bedini, A.; Spadoni, G.; Tarzia, G. Melatonin receptor agonists: SAR and applications to the treatment of sleepwake disorders. Curr. Top. Med. Chem., 2008, 8, 954-968.
283. Hardeland, R.; Poeggeler, B.; Srinivasan, V.; Trakht, I.; Pandi-Perumal, S.R.; Cardinali, D.P. Melatonergic drugs in clinical practice. Arzneimittelforschung, 2008, 58, 1-10.
284. Pandi-Perumal, S.R.; Trakht, I.; Srinivasan, V.; Spence, D.W.; Poeggeler, B.; Hardeland, R.; Cardinali, D.P. The effect of melatonergic and non-melatonergic antidepressants on sleep: weighing the alternatives. World J. Biol. Psychiatry, 2009, 10, 342-354.
285. Srinivasan, V.; Pandi-Perumal, S.R.; Trakht, I.; Spence, D.W.; Hardeland, R.; Poeggeler, B.; Cardinali, D.P. Pathophysiology of depression: role of sleep and the melatonergic system. Psychiatry Res., 2009, 165, 201-214.
286. Srinivasan, V.; Pandi-Perumal, S.R.; Trahkt, I.; Spence, D.W.; Poeggeler, B.; Hardeland, R.; Cardinali, D.P. Melatonin and melatonergic drugs on sleep: possible mechanisms of action. Int. J. Neurosci., 2009, 119, 821-846.
287. Ferguson, S.A.; Rajaratnam, S.M.; Dawson, D. Melatonin agonists and insomnia. Expert Rev. Neurother., 2010, 10, 305-318.
288. Hardeland, R. Melatonin and other sleep-promoting melatoninergic drugs under the aspects of binding properties and metabolism. In: Melatonin, Sleep and Insomnia; Soriento, Y.E. Ed.; Nova Science: Hauppauge, NY, 2010, pp. 273-290.
289. Srinivasan, V.; Cardinali, D.P.; Srinivasan, U.S.; Kaur, C.; Brown, G.M.; Spence, D.W.; Hardeland, R.; Pandi-Perumal, S.R. Therapeutic potential of melatonin and its analogs in Parkinson's disease: focus on sleep and neuroprotection. Ther. Adv. Neurol. Disord. 2011, 4, 297-317.
290. Srinivasan, V.; Brzezinski, A.; Pandi-Perumal, S.R.; Spence, D.W.; Cardinali, D.P.; Brown, G.M. Melatonin agonists in primary insomnia and depression-associated insomnia: are they superior to sedative-hypnotics? Prog. Neuropsychopharmacol. Biol. Psychiatry, 2011, 35, 913-923.
291. Spadoni, G.; Bedini, A.; Rivara, S.; Mor. M. Melatonin receptor agonists: new options for insomnia and depression treatment. CNS Neurosci. Ther., 2011, 17, 733-741.
292. Cardinali, D.P.; Pagano, E.S.; Scacchi Bernasconi, P.A.; Reynoso, R.; Scacchi, P. Disrupted chronobiology of sleep and cytoprotection in obesity: possible therapeutic value of melatonin. Neuroendocrinol. Lett., 2011, 32, 588-606.
293. McGechan, A.; Wellington, K. Ramelteon. CNS Drugs, 2005, 19, 1057-1065.
294. Stevenson, S.; Bryson, S.; Amayke, D.; Hibbert, M. Study to investigate the absolute bioavailability of a single oral dose of ramelteon (TAK-375) in healthy male subjects. Clin. Pharmacol. Ther. 2004, 75, P22.
295. Karim, A.; Tolbert, D.; Cao, C. Disposition kinetics and tolerance of escalating single doses of ramelteon, a high affinity MT1 and MT2 melatonin receptor agonist indicated for the treatment of insomnia. J. Clin. Pharmacol., 2006, 46, 140-148.
296. Pandi-Perumal, S.R.; Srinivasan, V.; Poeggeler, B.; Hardeland, R.; Cardinali, D.P. Drug insight: the use of melatonergic agonists for the treatment of insomnia-focus on ramelteon. Nat. Clin. Pract. Neurol., 2007, 3, 221-228.
297. Bourin, M.; Mocaër, E.; Porsolt, R. Antidepressant-like activity of S 20098 (agomelatine) in the forced swimming test in rodents: involvement of melatonin and serotonin receptors. J. Psychiatry Neurosci., 2004, 29, 126-133.
298. 2C receptors in Wistar rats. Psychopharmacology (Berl), 2003, 170, 17-22.
299. 2C receptors. Int. J. Neuropsychopharmacol., 2011, 14, 768-783.
300. Rajaratnam, S.M.W.; Polymeropoulos, M.H.; Fisher, D.M.; Roth, T.; Scott, C.; Birznieks, G.; Klerman, E.B. Melatonin agonist tasimelteon (VEC-162) for transient insomnia after sleep-time shift: Two randomised controlled multicentre trials. Lancet, 2009, 373, 482-491.
301. Cardinali, D.P.; Golombek, D.A. Let there be sleep-on time. Lancet, 2009, 373, 439-441.
302. Hardeland, R. Tasimelteon, a melatonin agonist for the treatment of insomnia and circadian rhythm sleep disorders. Curr. Opin. Investig. Drugs, 2009, 10, 691-701.
303. Mitkus, S.; Birznieks, G.; Thompson, A.; Lavedan, C. Effect of a period 3 (PER3) gene polymorphism on response to tasimelteon treatment in a phase advance model of transient insomnia. Sleep, 2009, 32, Suppl., A284.
304. Vachharajani, N.N.; Yeleswaram, K.; Boulton, D.W. Preclinical pharmacokinetics and metabolism of BMS-214778, a novel melatonin receptor agonist. J. Pharm. Sci., 2003, 92, 760-772.
305. Mulchahey, J.J.; Goldwater, D.R.; Zemlan, F.P. A single blind, placebo controlled, across groups dose escalation study of the safety, tolerability, pharmacokinetics and pharmacodynamics of the melatonin analog μ-methyl-6-chloromelatonin. Life Sci., 2004, 75, 1843-1856.
306. 2A/2C receptors: mutual improvement of sleep, cognition and mood? Eur. J. Neurosci., 2009, 29, 1795-809.
307. Rivara, S.; Vacondio, F.; Fioni, A.; Silva, C.; Carmi, C.; Mor, M.; Lucini, V.; Pannacci, M.; Caronno, A.; Scaglione, F.; Gobbi, G.; Spadoni, G.; Bedini, A.; Orlando, P.; Lucarini, S.; Tarzia, G. N-(Anilinoethyl)amides: design and synthesis of metabolically stable, selective melatonin receptor ligands. ChemMedChem, 2009, 4, 1746-1755.
308. Poeggeler, B.; Thuermann, S.; Dose, A.; Schoenke, M.; Burkhardt, S.; Hardeland, R. Melatonin's unique radical scavenging properties-Roles of its functional substituents as revealed by a comparison with its structural analogs. J. Pineal Res., 2002, 33, 20-30.
309. Zhu, M.; Mitroka, J.; Shaw, A.A.; Luke, G.M.; Vachharajani, N.; Kripalani, K.J. Identification of in vitro and in vivo metabolites of BMS-214778 in monkeys by ion trap LC/MS and LC/NMR. Drug Metab. Rev., 2000, 32, Suppl 2, 260.
310. Vachharajani, N.N.; Yeleswaram, K.; Boulton, D.W. Preclinical pharmacokinetics and metabolism of BMS-214778, a novel melatonin receptor agonist. J. Pharm. Sci., 2003, 92, 760-772.
311. Schyman, P.; Usharani, D.; Wang, Y.; Shaik, S. Brain chemistry: how does P450 catalyze the O-demethylation reaction of 5-methoxytryptamine to yield serotonin? J. Phys. Chem. B, 2010, 114, 7078-7089.
312. Kirchheiner, J.; Seeringer, A.; Godoy, A.L.; Ohmle, B.; Maier, C.; Beschoner, P.; Sim, E.J.; Viviani, R. CYP2D6 in the brain: genotype effects on resting brain perfusion. Mol. Psychiatry, 2011, 16, 333-341.
313. Stingl, J.C.; Viviani, R. CYP2D6 in the brain: impact on suicidality. Clin. Pharmacol. Ther., 2011, 89, 352-353.
314. Knüpfer, H.; Stanitz, D.; Preiss R. CYP2C9 polymorphisms in human tumors. Anticancer Res., 2006, 26, 299-305.
315. Bogaards, J.J.; Hissink, E.M.; Briggs, M.; Weaver, R.; Jochemsen, R.; Jackson, P.; Bertrand, M.; van Bladeren, P.J. Prediction of interindividual variation in drug plasma levels in vivo from individual enzyme kinetic data and physiologically based pharmacokinetic modeling. Eur. J. Pharm. Sci., 2000,12, 117-124.
316. Dolder, C.R.; Nelson, M.; Snider, M. Agomelatine treatment of major depressive disorder. Ann. Pharmacother., 2008, 42, 1822-1831.
317. Sánchez-Barceló, E.J.; Mediavilla, M.D.; Tan, D.-X.; Reiter, R.J. Clinical uses of melatonin: evaluation of human trials. Curr. Med. Chem., 2010, 17, 2070-2095.
318. Wilhelmsen, M.; Amirian, I.; Reiter, R.J.; Rosenberg, J.; Gögenur, I. Analgesic effects of melatonin: a review of current evidence from experimental and clinical studies. J. Pineal Res., 2011, 51, 270-277.
319. Mishima, K.; Okawa, M.; Hozumi, S.; Hishikawa, Y. Supplementary administration of bright light and melatonin as potent treatment for disorganized circadian rest-activity and dysfunctional autonomic and neuroendocrine systems in institutionalized demented elderly persons. Chronobiol. Int., 2000, 17, 419-432.
320. Pandi-Perumal, S.R.; Srinivasan, V.; Cardinali, D.P.; Monti, M.J. Could agomelatine be the ideal antidepressant? Expert Rev. Neurother., 2006, 6, 1595-1608.
321. Reynoldson, J.N.; Elliott, E. Sr.; Nelson, L.A. Ramelteon: a novel approach in the treatment of insomnia. Ann. Pharmacother., 2008, 42, 1262-1271.
322. Simpson, D.; Curran, M.P. Ramelteon: a review of its use in insomnia. Drugs, 2008, 68, 1901-1919.
323. Neubauer, D.N. A review of ramelteon in the treatment of sleep disorders. Neuropsychiatr. Dis. Treat., 2008, 4, 69-79.
324. Pandi-Perumal, S.R.; Trakht, I.; Spence, D.W.; Srinivasan, V.; Dagan, Y.; Cardinali, D.P. The roles of melatonin and light in the pathophysiology and treatment of circadian rhythm sleep disorders. Nat. Clin. Pract. Neurol., 2008, 4, 436-447.
325. Pandi-Perumal, S.R.; Srinivasan, V.; Spence, D.W.; Moscovitch, A.; Hardeland, R.; Brown, G.M.; Cardinali, D.P. Ramelteon: a review of its therapeutic potential in sleep disorders. Adv. Ther., 2009, 26, 613-626.
326. Fornaro, M.; Prestia, D.; Colicchio, S.; Perugi, G. A systematic, updated review on the antidepressant agomelatine focusing on its melatonergic modulation. Curr. Neuropharmacol., 2010, 8, 287-304.
327. Srinivasan, V.; Singh, J.; Pandi-Perumal, S.R.; Brown, G.M.; Spence, D.W.; Cardinali, D.P. Jet lag, circadian rhythm sleep disturbances, and depression: the role of melatonin and its analogs. Adv. Ther., 2010, 27, 796-813.
328. De Berardis, D.; Di Iorio, G.; Acciavatti, T.; Conti, C.; Serroni, N.; Olivieri, L.; Cavuto, M.; Martinotti, G.; Janiri, L.; Moschetta, F.S.; Conti, P.; Di Giannantonio, M. The emerging role of melatonin agonists in the treatment of major depression: focus on agomelatine. CNS Neurol. Disord. Drug Targets, 2011, 10, 119-132.
329. Green, B. Focus on agomelatine. Curr. Med. Res. Opin., 2011, 27, 745-749.
330. Carney, R.M.; Shelton, R.C. Agomelatine for the treatment of major depressive disorder. Expert Opin. Pharmacother., 2011, 12, 2411-2419.
331. Cardinali, D.P.; Srinivasan, V.; Brzezinski, A.; Brown, G.M. Melatonin and its analogs in insomnia and depression. J. Pineal Res., 2011, 52, 365-375.
332. Korkmaz, A.; Reiter, R.J.; Topal, T.; Manchester, L.C.; Oter, S.; Tan, D.-X. Melatonin: an established antioxidant worthy of use in clinical trials. Mol. Med., 2009, 15, 43-50.
333. Sjöholm, L.K.; Backlund, L.; Cheteh, E.H.; Ek, I.R.; Frisén, L.; Schalling, M.; Osby, U.; Lavebratt. C.; Nikamo, P. CRY2 is associated with rapid cycling in bipolar disorder patients. PLoS One, 2010, 5, e12632.
334. Srinivasan, V.; Smits, M.; Spence, W.; Lowe, A.D.; Kayumov, L.; Pandi-Perumal, S.R.; Parry, B.; Cardinali, D.P. Melatonin in mood disorders. World J. Biol. Psychiatry, 2006, 7, 138-151.
335. Lewy, A.J.; Rough, J.N.; Songer, J.B.; Mishra, N.; Yuhas, K.; Emens, J.S. The phase shift hypothesis for the circadian component of winter depression. Dialogues Clin. Neurosci., 2007, 9, 291-300.
336. Lamont, E.W.; Legault-Coutu, D.; Cermakian, N.; Boivin, D.B. The role of circadian clock genes in mental disorders. Dialogues Clin. Neurosci., 2007, 9, 333-342.
337. McClung, C.A. Circadian genes, rhythms and the biology of mood disorders. Pharmacol. Ther., 2007, 114, 222-232.
338. Westrin, A.; Lam, R.W. Seasonal affective disorder: A clinical update. Ann. Clin. Psychiatry, 2007, 19, 239-246.
339. Lewy, A.J. Melatonin and human chronobiology. Cold Spring Harbor Symp. Quant. Biol., 2007, 72, 623-636.
340. Hardeland, R. Neurobiology, pathophysiology, and treatment of melatonin deficiency and dysfunction. Sci. Worl. J., 2012, in press.
341. Pandi-Perumal, S.R.; Spence, D.W.; Verster, J.C.; Srinivasan, V.; Brown, G.M.; Cardinali, D.P.; Hardeland, R. Pharmacotherapy of insomnia with ramelteon: Safety, efficacy and clinical applications. J. Cent. Nerv. Syst. Dis., 2011, 3, 51-65.
342. Erman, M.; Seiden, D.; Zammit, G.; Sainati, S.; Zhang, J. An efficacy, safety, and dose-response study of ramelteon in patients with chronic primary insomnia. Sleep Med., 2006, 7, 17-24.
343. Roth, T.; Seiden, D.; Sainati, S.; Wang-Weigand, S.; Zhang, J.; Zee, P. Effects of ramelteon on patient-reported sleep latency in older adults with chronic insomnia. Sleep Med., 2006, 7, 312-318.
344. Zemlan, F.P.; Mulchahey, J.J.; Scharf, M.B.; Mayleben, D.W.; Rosenberg, R.; Lankford, A. The efficacy and safety of the melatonin agonist μ-methyl-6-chloromelatonin in primary insomnia: a randomized, placebo-controlled, crossover clinical trial. J. Clin. Psychiatry, 2005, 66, 384-390.
345. Pandi-Perumal, S.R.; Moscovitch, A.; Srinivasan, V.; Spence, D.W.; Cardinali, D.P.; Brown, G.M. Bidirectional communication between sleep and circadian rhythms and its implications for depression: lessons from agomelatine. Prog. Neurobiol., 2009, 88, 264-271.
346. Quera-Salva, M.A.; Hajak, G.; Philip, P.; Montplaisir, J.; Keufer-Le Gall, S.; Laredo, J.; Guilleminault, C. Comparison of agomelatine and escitalopram on nighttime sleep and daytime condition and efficacy in major depressive disorder patients. Int. Clin. Psychopharmacol., 2011, 26, 252-262.
347. Weishaupt, J.H.; Bartels, C.; Pölking, E.; Dietrich, J.; Rohde, G.; Poeggeler, B.; Mertens, N.; Sperling, S.; Bohn, M.; Hüther, G.; Schneider, A.: Bach, A.; Sirén, A.L.; Hardeland, R.; Bähr, M.; Nave, K.A.; Ehrenreich, H. Reduced oxidative damage in ALS by high-dose enteral melatonin treatment. J. Pineal Res., 2006, 41, 313-323.
348. Silman, R. Melatonin and the human gonadotrophin-releasing hormone pulse generator. J. Endocrinol., 1991, 128, 7-11.
349. Waldhauser, F.; Boepple, P.A.; Schemper, M.; Mansfield, M.J.; Crowley, W.F. Jr. Serum melatonin in central precocious puberty is lower than in age-matched prepubertal children. J. Clin. Endocrinol. Metab., 1991, 73, 793-796.
350. Walker, A.B.; English, J.; Arendt, J.; MacFarlane, I.A. Hypogonadotrophic hypogonadism and primary amenorrhoea associated with increased melatonin secretion from a cystic pineal lesion. Clin. Endocrinol. (Oxf.), 1996, 45, 353-356.
351. Luboshitzky, R.; Herer, P.; Shen-Orr, Z. Urinary 6-sulfatoxymelatonin excretion in hyperandrogenic women: the effect of cyproterone acetate-ethinyl estradiol treatment. Exp. Clin. Endocrinol. Diabetes, 2004, 112, 102-107.
352. Rohr, U.D.; Herold, J. Melatonin deficiencies in women. Maturitas, 2002, 41, Suppl 1, S85-S104.
353. Luboshitzky, R.; Shen-Orr, Z.; Nave, R.; Lavi, S.; Lavie, P. Melatonin administration alters semen quality in healthy men. J. Androl., 2002, 23, 572-578.
354. Willis, G.L. The role of ML-23 and other melatonin analogues in the treatment and management of Parkinson's disease. Drug News Perspect., 2005, 18, 437-444.
355. Power, A.E. Slow-wave sleep, acetylcholine, and memory consolidation. Proc. Natl. Acad. Sci. USA, 2004, 101, 1795-1796.
356. Gais, W.; Born, J. Low acetylcholine during slow-wave sleep is critical for declarative memory consolidation. Proc. Natl. Acad. Sci. USA, 2004, 101, 2140-2144.
357. Nieoullon, A.; Bentué-Ferrer, D.; Bordet, R.; Tsolaki, M.; Förstl, H. Importance of circadian rhythmicity in the cholinergic treatment of Alzheimer's disease: focus on galantamine. Curr. Med. Res. Opin., 2008, 24, 3357-3367.
358. Rawashdeh, O.; de Borsetti, N.H.; Roman, G.; Cahill, G.M. Melatonin suppresses nighttime memory formation in zebrafish. Science, 2007, 318, 1144-1146.
359. Olcese, J.M.; Cao, C.; Mori, T.; Mamcarz, M.B.; Maxwell, A.; Runfeldt, M.J.; Wang, L.; Zhang, C.; Lin, X.; Zhang, G.; Arendash, G.W. Protection against cognitive deficits and markers of neurodegeneration by long-term oral administration of melatonin in a transgenic model of Alzheimer disease. J. Pineal Res., 2009, 47, 82-96.
360. Zhdanova, I.V. Sleep and its regulation in zebrafish. Rev. Neurosci., 2011, 22, 27-36.
361. Kunz, D.; Mahlberg, R.; Müller, C.; Tilmann, A.; Bes, F. Melatonin in patients with reduced REM sleep duration: two randomized controlled trials. J. Clin. Endocrinol. Metab., 2004, 89, 128-134.
362. Zammit, G.; Erman, M.; Wang-Weigand, S.; Sainati, S.; Zhang, J.; Roth, T. Evaluation of the efficacy and safety of ramelteon in subjects with chronic insomnia. J. Clin. Sleep Med., 2007, 3, 495-504.
363. Mayer, G.; Wang-Weigand, S.; Roth-Schechter, B.; Lehmann, R.; Staner, C.; Partinen, M. Efficacy and safety of 6-month nightly ramelteon administration in adults with chronic primary insomnia. Sleep, 2009, 3, 351-360.
364. Lopes, M.C.; Quera-Salva, M.A.; Guilleminault, C. Non-REM sleep instability with major depressive disorder: subjective improvement and improvement of non-REM instability with treatment (Agomelatine). Sleep Med., 2007, 9, 33-41.
365. 2 melatonin receptor ligand. J. Neurosci., 2011, 31, 18439-18452.
366. Roth, T.; Seiden, D.; Wang-Weigand, S.; Zhang, J. A 2-night, 3-period, crossover study of ramelteon's efficacy and safety in older adults with chronic insomnia. Curr. Med. Res. Opin., 2007, 23, 1005-1014.
367. Kryger, M.; Wang-Weigand, S.; Roth, T. Safety of ramelteon in individuals with mild to moderate obstructive sleep apnea. Sleep Breath, 2007, 11, 159-164.
368. Sateia, M.J.; Kirby-Long, P.; Taylor J.L. Efficacy and clinical safety of ramelteon: an evidence-based review. Sleep Med. Rev., 2008, 12, 319-332.
369. Wade, A.; Downie, S. Prolonged-release melatonin for the treatment of insomnia in patients over 55 years. Expert Opin. Investig. Drugs, 2008, 17, 1567-1572.
370. Richardson, G.S.; Zammit, G.; Wang-Weigand, S.; Zhang, J. Safety and subjective sleep effects of ramelteon administration in adults and older adults with chronic primary insomnia: a 1-year, open-label study. J. Clin. Psychiatry, 2009, 70, 467-476.
371. Wade, A.G.; Ford, I.; Crawford, G.; McConnachie, A.; Nir, T.; Laudon, M.; Zisapel, N. Nightly treatment of primary insomnia with prolonged release melatonin for 6 months: a randomized placebo controlled trial on age and endogenous melatonin as predictors of efficacy and safety. BMC Med., 2010, 8, 51.
372. Lemoine, P.; Garfinkel, D.; Laudon, M.; Nir, T.; Zisapel, N. Prolonged-release melatonin for insomnia-an open-label longterm study of efficacy, safety, and withdrawal. Ther. Clin. Risk Manag., 2011, 7, 301-311.
373. Garfinkel, D.; Zorin, M.; Wainstein, J.; Matas, Z.; Laudon, M.; Zisapel, N. Efficacy and safety of prolonged-release melatonin in insomnia patients with diabetes: a randomized, double-blind, crossover study. Diabetes Metab. Syndr. Obes., 2011, 4, 307-313.
374. Demyttenaere, K. Agomelatine: a narrative review. Eur. Neuropsychopharmacol., 2011, 21, Suppl. 4, S703-S709.
375. Lemoine, P.; Zisapel, N. Prolonged-release formulation of melatonin (Circadin) for the treatment of insomnia. Expert Opin. Pharmacother., 2012, 13, 895-905.
376. Lemoine, P.; Wade, A.G.; Katz, A.; Nir, T.; Zisapel, N. Efficacy and safety of prolonged-release melatonin for insomnia in middle-aged and elderly patients with hypertension: a combined analysis of controlled clinical trials. Integr. Blood Press. Control, 2012, 5, 9-17.
377. Uchiyama, M.; Hamamura, M.; Kuwano, T.; Nagata, H.; Hashimoto, T.; Ogawa, A.; Uchimura, N. Long-term safety and efficacy of ramelteon in Japanese patients with chronic insomnia. Sleep Med., 2011, 12, 127-133.
378. Stahl, S.M.; Fava, M.; Trivedi, M.H.; Caputo, A.; Shah, A.; Post, A. Agomelatine in the treatment of major depressive disorder: an 8-week, multicenter, randomized, placebo-controlled trial. J. Clin. Psychiatry, 2010, 71, 616-626.
379. Zajecka, J.; Schatzberg, A.; Stahl, S.; Shah, A.; Caputo, A.; Post, A. Efficacy and safety of agomelatine in the treatment of major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled trial. J. Clin. Psychopharmacol., 2010, 30, 135-144.
380. Anonymous. Agomelatine: new drug. Adverse effects and no proven efficacy. Prescrire Int., 2009, 18, 241-245.
381. Howland, R.H. Publication bias and outcome reporting bias: agomelatine as a case example. J. Psychosoc. Nurs. Ment. Health Serv., 2011, 49, 11-14.
382. Neville, S.; Arendt, J.; Ioannides, C. A study of the mutagenicity of melatonin and 6-hydroxymelatonin. J. Pineal Res., 1989, 6, 73-76.
383. Anisimov, V.N. Premature ageing prevention: Limitations and perspectives of pharmacological interventions. Curr. Drug Targets, 2006, 7, 1485-1503.
384. Reiter, R.J. Oxidative damage to nuclear DNA: amelioration by melatonin. Neuroendocrinol. Lett., 1999, 20, 145-150.
385. Anisimov, V.N.; Popovich, I.G.; Zabezhinski, M.A.; Anisimov, S.V.; Vesnushkin, G.M.; Vinogradova, I.A. Melatonin as antioxidant, geroprotector and anticarcinogen. Biochim. Biophys. Acta, 2006, 1757, 573-589.
386. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA). Scientific Opinion on the substantiation of health claims related to melatonin and alleviation of subjective feelings of jet lag (ID 1953), and reduction of sleep onset latency, and improvement of sleep quality (ID 1953) pursuant to Article 13 (1) of Regulation (EC) No 1924/20061. EFSA J., 2010, 8, 1461.
387. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA). Scientific Opionion on the substantiation of a health claim related to melatonin and reduction of sleep onset latency (ID 1698; 1780, 4080) pursuant to Article 13 (1) of Regulation (EC) No 1924/2006. EFSA J., 2011, 9, 2241.
388. Murch, S.J.; Saxena, P.K. A melatonin-rich germplasm line of St. John's wort (Hypericum perforatum L.). J. Pineal Res., 2006, 41, 284-287.
389. Komoroski, B.J.; Zhang, S.; Cai, H.; Hutzler, J.M.; Frye, R.; Tracy, T.S.; Strom, S.C.; Lehmann, T.; Ang, C.Y.W.; Cui, Y.Y.; Venkataramanan, R. Induction and inhibition of cytochromes P450 by the St. John's wort constituent hyperforin in human hepatocyte cultures. Drug Metab. Dispos., 2004, 32, 512-518.